Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.


TSX:TH - Post by User

Comment by scarlet1967on Feb 11, 2021 9:49am
78 Views
Post# 32536448

RE:RE:RE:Financial Results to be Released Feb. 25.

RE:RE:RE:Financial Results to be Released Feb. 25.Emailed the below to her.


what Leah should be doing is using the fat fee they just paid to the 3 banks to make them ask important leading questions they want to discuss and have on the transcript.  She needs to ask each of them to ask 1 or 2 specific questions so they can elaborate and turn this into something useful.  This is, by the way, done all the time and perfectly acceptable.  If I were her I would make Mackie ask something like, explain the Phase 1 timeline expectations, clarify the data in P1 that could immediately go to P2, what is the importance of targeting a scavenger receptor vs. non-scavenger, etc...   then have NBF dig in to NASH protocol, timing, abilit6 to harmonize, why they think there's such a value discrepancy between them and others, they keep talk8ng about incorporating the latest NASH info, what specifically is that, etc...    If she doesn't do this they will be missing a chance to educate investors as they want,  Thise transcripts are printed and published.  This is your once a quarter chance to elucidate and add depth to your discussions.  Two softball questions from sleepy analysts should embarrass them.  Get your moneies worth from thos fat fees you just paid put and turn this from something embarrassing to something useful.  

[/quote]

<< Previous
Bullboard Posts
Next >>

USER FEEDBACK SURVEY ×

Be the voice that helps shape the content on site!

At Stockhouse, we’re committed to delivering content that matters to you. Your insights are key in shaping our strategy. Take a few minutes to share your feedback and help influence what you see on our site!

The Market Online in partnership with Stockhouse